These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28542590)

  • 1. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
    Aristizabal Prada ET; Orth M; Nölting S; Spöttl G; Maurer J; Auernhammer C
    PLoS One; 2017; 12(5):e0178375. PubMed ID: 28542590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
    BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures.
    van der Waals LM; Laoukili J; Jongen JMJ; Raats DA; Borel Rinkes IHM; Kranenburg O
    Sci Rep; 2019 Jan; 9(1):819. PubMed ID: 30692572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
    Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
    Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway.
    Gul N; Karlsson J; Tängemo C; Linsefors S; Tuyizere S; Perkins R; Ala C; Zou Z; Larsson E; Bergö MO; Lindahl P
    Sci Rep; 2019 Oct; 9(1):14667. PubMed ID: 31604991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling.
    Zhan D; Zhang X; Li J; Ding X; Cui Y; Jia J
    Cancer Biother Radiopharm; 2020 Apr; 35(3):223-232. PubMed ID: 32077746
    [No Abstract]   [Full Text] [Related]  

  • 12. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive Oxygen Species Dictate the Apoptotic Response of Melanoma Cells to TH588.
    Wang JY; Jin L; Yan XG; Sherwin S; Farrelly M; Zhang YY; Liu F; Wang CY; Guo ST; Yari H; La T; McFarlane J; Lei FX; Tabatabaee H; Chen JZ; Croft A; Jiang CC; Zhang XD
    J Invest Dermatol; 2016 Nov; 136(11):2277-2286. PubMed ID: 27427486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extract of
    Cui XL; Li KJ; Ren HX; Zhang YJ; Liu XD; Bu BG; Wang L
    World J Gastroenterol; 2019 Apr; 25(15):1854-1864. PubMed ID: 31057299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
    Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
    J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.